Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL464495 | 0.85 | TGM2 (0.53) | MAPTTGM2FOLH1HTTPOLB | |
| SCHEMBL4541834 | 0.81 | MAPT (0.56) | MAPTTGM2FOLH1HTTTPSAB1 | |
| SCHEMBL1882392 | 0.81 | MAPT (0.56) | MAPTTGM2FOLH1HTTTPSAB1 | |
| SCHEMBL31490054 | 0.80 | HTT (0.54) | MAPTTGM2FOLH1HTTL3MBTL1 | |
| SCHEMBL9667908 | 0.79 | HTT (0.61) | MAPTTGM2FOLH1HTTL3MBTL1 | |
| SCHEMBL25787604 | 0.79 | HTT (0.61) | MAPTTGM2FOLH1HTTL3MBTL1 | |
| SCHEMBL3052852 | 0.79 | HTT (0.61) | MAPTTGM2FOLH1HTTL3MBTL1 | |
| SCHEMBL20385193 | 0.79 | MAPT (0.64) | MAPTTGM2HTTPOLBMAPK1 | |
| SCHEMBL15679441 | 0.79 | MAPT (0.64) | MAPTTGM2HTTPOLBMAPK1 | |
| SCHEMBL13090607 | 0.79 | MAPT (0.64) | MAPTTGM2HTTPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-10-15 | — | — | US | disclosed |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2020-02-13 | — | — | US | disclosed |
| EP-3566719-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASES | Cerulean Pharma Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2018-04-26 | — | — | US | disclosed |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2017-12-28 | — | — | US | disclosed |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2015-01-01 | — | — | US | disclosed |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | CERULEAN PHARMA INC. | 2012-08-23 | — | — | US | disclosed |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | GLUCKSMANN ALEXANDRA (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012044832-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | FETZER OLIVER S (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | CERULEAN PHARMA INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2012-01-05 | — | — | US | disclosed |
| WO-2011090940-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110178287-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CERULEAN PHARMA INC. | 2011-07-21 | — | — | US | disclosed |
| WO-2010114770-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | CERULEAN PHARMA INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180110791-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | MAPT 402/4885TGM2 2716/4885FOLH1 1923/4885 |
| US-20170368194-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | MAPT 453/4885TGM2 435/4885FOLH1 1477/4885 |
| US-20180193486-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | MAPT 2965/4885TGM2 209/4885FOLH1 190/4885 |
| US-20120202772-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | MAPT 402/4885TGM2 2716/4885FOLH1 1923/4885 |
| US-20100247669-A1 | POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE | LPXN, POLI, BRCA1 | MAPT 467/4885TGM2 1162/4885FOLH1 371/4885 |
| US-20120004195-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | MAPT 402/4885TGM2 2716/4885FOLH1 1923/4885 |
| US-20120064107-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | MAPT 2965/4885TGM2 209/4885FOLH1 190/4885 |
| US-20140328918-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | MAPT 1897/4885TGM2 1016/4885FOLH1 1019/4885 |
| US-20130059816-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE | PHOSPHO1, SGMS1, SGMS2 | MAPT 2965/4885TGM2 209/4885FOLH1 190/4885 |
| US-20200323889-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | MAPT 402/4885TGM2 2716/4885FOLH1 1923/4885 |
| US-20200046845-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | MAPT 453/4885TGM2 435/4885FOLH1 1477/4885 |
| US-20120213854-A1 | METHODS OF TREATING A SUBJECT AND RELATED PARTICLES, POLYMERS AND COMPOSITIONS | HLA-DRB1, TSG101, IAPP | MAPT 1897/4885TGM2 1016/4885FOLH1 1019/4885 |
| US-20150005230-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | MAPT 453/4885TGM2 435/4885FOLH1 1477/4885 |
| US-20160058874-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | CDR2, DDOST, GALC | MAPT 453/4885TGM2 435/4885FOLH1 1477/4885 |
| US-20140378414-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY | PSMG3, COPB1, PSMA6 | MAPT 402/4885TGM2 2716/4885FOLH1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.